In this review we describe a series of major concepts introduced during the past 150years that have contributed to our current understanding about how physiological processes required for well-being and survival are regulated. One can theorize that hierarchical networks involving input-output relationships continuously orchestrate and learn adaptive patterns of observable behaviors, cognition, memory, mood, and autonomic systems. Taken together, these networks function as "good regulators" determining levels of internal variables and act as if there were homeostatic comparators ("homeostats"). The consequences of models with vs. without homeostats remain the same in terms of allostatic load and the eventual switch from stabilizing negative feedback loops to destabilizing, pathogenic positive feedback loops. Understanding this switch seems important for comprehending senescence-related, neurodegenerative disorders that involve the autonomic nervous system. Our general proposal is that disintegration of homeostatic systems causes disorders of regulation in degenerative diseases and that medical cybernetics can inspire and rationalize new approaches to treatment and prevention.

Fetal hypoxia triggers compensatory angiogenesis and remodeling through mechanisms not fully elucidated. In response to hypoxia, hypoxia-inducible factor drives expression of cytokines that exert multiple effects on cerebral structures. Among these, the artery wall is composed of a heterogeneous cell mix and exhibits distinct patterns of cellular differentiation and reactivity. Governing these patterns are the vascular endothelium, smooth muscle (SM), adventitia, sympathetic perivascular nerves (SPN), and the parenchyma. Although an extensive literature details effects of nonneuronal factors on cerebral arteries, the trophic role of perivascular nerves remains unclear. Hypoxia increases sympathetic innervation with subsequent release of norepinephrine (NE), neuropeptide-Y (NPY), and adenosine triphosphate, which exert motor and trophic effects on cerebral arteries and influence dynamic transitions among SM phenotypes. Our data also suggest that the cerebrovasculature reacts very differently to hypoxia in fetuses and adults, and we hypothesize that these differences arise from age-related differences in arterial SM phenotype reactivity and proximity to trophic factors, particularly of neural origin. We provide an integration of recent literature focused on mechanisms by which SPN mediate hypoxic remodeling. Our recent findings suggest that trophic effects of SPN on cerebral arteries accelerate functional maturation through shifts in SM phenotype in an age-dependent manner.

Neuropeptide Y (NPY) is a neuropeptide widely expressed in the brain and a peptide transmitter of sympathetic nervous system (SNS) co-released with noradrenaline (NA) in prolonged stress. Association of a gain-of-function polymorphism in the human NPY gene with dyslipideamia, diabetes and vascular diseases suggests that increased NPY plays a role in the pathogenesis of the metabolic syndrome in humans. In the hypothalamus, NPY plays an established role in the regulation of body energy homeostasis. However, the effects of NPY elsewhere in the brain and in the SNS are less explored. In order to understand the role of NPY co-expressed with NA in the sympathetic nerves and brain noradrenergic neurons, a novel mouse model overexpressing NPY in noradrenergic neurons was generated. The mouse displays metabolic defects such as increased adiposity, hepatosteatosis, and impaired glucose tolerance as well as stress-related hypertension and increased susceptibility to vascular wall hypertrophy. The mouse phenotype closely reflects the findings of the several association studies with human NPY gene polymorphisms, and fits with the previous work on the effects of stress-induced NPY release on metabolism and vasculature. Thus, in addition of promoting feeding and obesity in the hypothalamus, NPY expressed in the noradrenergic neurons in the brain and in the SNS induces the development of cardiometabolic diseases.

The distributions of classical and putative neurotransmitters within somata and fibres of the dorsal vagal complex are reviewed. The occurrence within the dorsal medulla oblongata of receptors specific for some of these substances is examined, and possible functional correlations of the specific neurochemicals with respect to their distribution within the dorsal vagal complex are discussed. Many of the known transmitters and putative transmitters are represented in the dorsal vagal complex, particularly within various subnuclei of the nucleus of the solitary tract, the main vagal afferent nucleus. In a few cases, some of these have been examined in detail, particularly with respect to their possible mediation of cardiovascular or gastrointestinal functions. For example, the catecholamines, substance P and angiotensin II in the nucleus of the solitary tract have all been strongly implicated as playing a role in the central control of cardiovascular function. Other neurotransmitters or putative transmitters may be involved as well, but probably to a lesser extent. Similarly, the roles in the dorsal vagal complex of dopamine, the endorphins and cholecystokinin in control of the gut have been studied in some detail. Future investigations of the distributions of and electrophysiological parameters of neurotransmitters at the cellular level should provide much needed clues to advance our knowledge of the correlations between anatomical distributions of specific neurochemicals and physiological functions mediated by them.

Neuropeptide Y (NPY) is a 36 amino acid peptide, which among others, plays a pivotal role in stress response. Although previous studies confirmed that NPY release is increased by stress in several species, the exact mechanism of the stress-induced NPY release has not been elucidated yet. In the present study, we examined, with morphological means, the possibility that catecholamines directly influence NPY release in the human hypothalamus. Since the use of electron microscopic techniques is virtually impossible in immunostained human samples due to the long post mortem time, double-label immunohistochemistry was utilised in order to reveal the putative catecholaminergic-NPY associations. The present study is the first to demonstrate juxtapositions between the catecholaminergic, tyrosine hydroxylase (TH)/dopamine-beta hydroxylase (DBH)-immunoreactive (IR) and NPY-IR neural elements in the human hypothalamus. These en passant type associations are most numerous in the infundibular and periventricular areas of the human diencephalon. Here, NPY-IR neurons often form several contacts with catecholaminergic fibre varicosities, without any observable gaps between the contacting elements, suggesting that these juxtapositions may represent functional synapses. The lack of phenylethanolamine N-methyltransferase (PNMT)-NPY juxtapositions and the relatively few observed DBH-NPY associations suggest that the vast majority of the observed TH-NPY juxtapositions represent dopaminergic synapses. Since catecholamines are known to be the crucial components of the stress response, the presence of direct, catecholaminergic (primarily dopaminergic)-NPY-IR synapses may explain the increased NPY release during stress. The released NPY in turn is believed to play an active role in the responses that are directed to maintain the homeostasis during stressful conditions.

The scientific understanding of preproglucagon derived peptides has provided people with type 2 diabetes with two novel classes of glucose lowering agents, the dipeptidyl peptidase IV (DPP-IV) inhibitors and GLP-1 receptor agonists. For the scientists, the novel GLP-1 agonists, and DPP-IV inhibitors have evolved as useful tools to understand the role of the preproglucagon derived peptides in normal physiology and disease. However, the overwhelming interest attracted by GLP-1 analogues as potent incretins has somewhat clouded the efforts to understand the importance of preproglucagon derived peptides in other physiological contexts. In particular, our neurobiological understanding of the preproglucagon expressing neuronal pathways in the central nervous system as well as the degree to which central GLP-1 receptors are targeted by peripherally administered GLP-1 receptor agonists is still fairly limited. The role of GLP-1 as an anorectic neurotransmitter is well recognized, but clarification of the neuronal targets and physiological basis of this response is further warranted, as is the mapping of GLP-1 sensitive neurons involved in a variety of neuroendocrine and behavioral responses. Further recent evidence points to GLP-1 as a central neuropeptide with neuroprotective capabilities potentially mitigating a wide array of neurodegenerative conditions. It is the aim of the present review to summarize our current understanding of preproglucagon derived peptides as neurotransmitters in the central nervous system.

Outcome in anorexia nervosa remains poor and a new way of looking at this condition is therefore needed. To this aim, we review the effects of food restriction and starvation in humans. It is suggested that body weight remains stable and relatively low when the access to food requires a considerable amount of physical activity. In this condition, the human homeostatic phenotype, body fat content is also low and as a consequence, the synthesis and release of brain neurotransmitters are modified. As an example, the role of neuropeptide Y is analyzed in rat models of this state. It is suggested that the normal behavioral role of neuropeptide Y is to facilitate the search for food and switch attention from sexual stimuli to food. Descriptive neuroendocrine studies on patients with anorexia nervosa have not contributed to the management of the patients and the few studies in which hormones have been administered have, at best, reversed an endocrine consequence secondary to starvation. In a modified framework for understanding the etiology and treatment of anorexia nervosa it is suggested that the condition emerges because neural mechanisms of reward and attention are engaged. The neural neuropeptide Y receptor system may be involved in the maintenance of the behavior of eating disorder patients because the localization of these receptors overlaps with the neural systems engaged in cue-conditioned eating in limbic and cortical areas. The eating behavior of patients with anorexia nervosa, and other eating disorders as well, is viewed as a cause of the psychological changes of the patients. Patients are trained to re-learn normal eating habits using external support and as they do, their symptoms, including the psychological symptoms, dissolve.

Neuropeptide FF-like immunoreactive (NPFFir) cells and fibers were analyzed through development of Xenopus laevis. The first NPFFir cells appeared in the embryonic hypothalamus, which projected to the intermediate lobe of the hypophysis, the brainstem and spinal cord. Slightly later, scattered NPFFir cells were present in the olfactory bulbs and ventral telencephalon. In the caudal medulla, NPFFir cells were observed in the nucleus of the solitary tract only at embryonic and early larval stages. Abundant NPFFir cells and fibers were demonstrated in the spinal cord. The sequence of appearance observed in Xenopus shares many developmental features with mammals although notable differences were observed in the telencephalon and hypothalamus. In general, NPFF immunoreactivity developed earlier in amphibians than in mammals.

Reverse transcription polymerase chain reaction (RT-PCR) studies identified the mRNA coding for the Y1 and Y2 receptors in human mammary artery/vein and saphenous vein biopsies. Y1 receptors are expressed in vascular smooth muscles and potentiate the contractile action of sympathetic co-transmitters, adenosine triphosphate (ATP) and noradrenaline (NA); BIBP 3226, a competitive Y1 receptor antagonist, blocked the neuropeptide Y (NPY)-induced modulation. The Y2 receptor is expressed in sympathetic nerves terminals and modulates the pool of sympathetic co-transmitters released at the neuroeffector junction. NPY plays a dual role as a modulator of sympathetic co-transmission; it facilitates vascular smooth muscle reactivity and modulates the presynaptic release of ATP and NA. Sympathetic reflexes regulate human vascular resistance, where NPY plays a modulator role of paramount importance following increased sympathetic discharges, such as stress and vascular disease.

Prolactin-releasing peptide (PrRP) and neuropeptide FF (NPFF) are RF-amide peptides expressed in brain areas involved in pain modulation. NPFF displays multiple effects on acute, inflammatory and neuropathic pain. The potential role of PrRP in pain was addressed by intrathecal and intracerebral injections of PrRP on pain-related responses in both neuropathic and normal rats. Particularly in the dorsal medulla, PrRP produced significant antinociception in normal rats and an antiallodynic effect in neuropathic rats. To understand the basis of PrRP-induced pain modulation, distributions of PrRP, PrRP receptor, and NPFF were compared in the rat central nervous system. PrRP and NPFF mRNA were expressed in different parts of the nucleus of the solitary tract. In the medulla, PrRP receptor mRNA expression was abundant only in area postrema. Of the peptides studied, only NPFF mRNA was found in the dorsal horn of the spinal cord and spinal nucleus of the trigeminal nerve. PrRP-immunoreactivity corresponded to the mRNA distribution. Even if the neuronal groups producing NPFF and PrRP were distinct, the fiber networks immunoreactive for PrRP and NPFF overlapped. The results show that PrRP modulates nociception due to supraspinal rather than spinal action, and that its antinociceptive mechanism differs from that previously characterized for NPFF.

FLFQPQRF-NH2 (F8Famide; morphine-modulating peptide), isolated from bovine brain, is an FMRFamide-like peptide with opioid analgesia modulating effects. In the rat brain, F8Famide is immunohistochemically localized in neurons of the medial hypothalamus and medulla oblongata. Neuropeptide Y (NPY) is structurally related to F8Famide and the mammalian FMRFamide-like immunoreactivity (LI) was once thought to be due to an NPY-like peptide. We compared the anatomical distribution of F8Famide-LI with the localization of enkephalin- and NPY-LI-containing structures in the rat brain to find out if NPY or enkephalins coexist with F8Famide-LI. Cryostat sections of colchicine-treated Wistar rat brains were incubated with specific antisera against F8Famide, NPY, YGGFMRGL (Met-enkephalin-Arg-Gly-Leu), or YGGFMRF (Met-enkephalin-Arg-Phe) raised in rabbits. The immunoreactivity was visualized by the peroxidase - antiperoxidase or immunofluorescence method. The light microscopic mirror method was applied to study the colocalization of F8Famide and NPY. The F8Famide-immunoreactivity was concentrated in smaller areas of medial hypothalamus and nucleus of the solitary tract than that of enkephalins and NPY. In all brain areas, the distributions of F8Famide-, enkephalin- and NPY-immunoreactive neurons were distinct. F8Famide-, NPY- and enkephalin-LI-containing nerve terminals were seen in the nucleus of the solitary tract and in the lateral parabrachial nucleus. These results show that the neuronal systems containing F8Famide-, enkephalin- or NPY-LI are anatomically separate in all brain regions. However, there are terminal areas in which more than one type of these immunoreactivities are detected. These results have anatomical correlation with pharmacological reports, suggesting modulatory functions for these peptides on regulation of blood pressure, feeding behaviour and endocrine functions.

Neuropeptide Y displays diverse modes of action in the CNS including the modulation of cortical/limbic function. Some of these physiological actions have been at least partially attributed to actions of neuropeptide Y on the Y5 receptor subtype. We utilized an antibody raised against the Y5 receptor to characterize the distribution of this receptor subtype in the rat cortical/limbic system and brainstem. Y5-like immunoreactivity was located primarily in neuronal cell bodies and proximal dendritic processes throughout the brain. In the cortex, Y5 immunoreactivity was limited to a subpopulation of small gamma-aminobutyric-acid interneurons (approximately 15 microm diameter) scattered throughout all cortical levels. Double label immunofluorescence was also used to demonstrate that all of the Y5 immunoreactive neurons in the cortex displayed intense corticotropin releasing hormone immunoreactivity. The most intense Y5 immunoreactive staining in the hippocampus was located in the pyramidal cell layer of the small CA2 subregion and the fasciola cinerea, with lower levels of staining in the hilar region of the dentate gyrus and CA3 subregion of the pyramidal cell layer. Nearly all of the Y5 immunoreactive neurons in the hilar region of the hippocampus displayed gamma-aminobutyric-acid immunoreactivity. In the brainstem, Y5 immunoreactivity was most intense in the Edinger-Westphal nucleus, locus coeruleus and the mesencephalic trigeminal nucleus. The present study provides neuroanatomical evidence for the possible sites of action of the neuropeptide Y/Y5 receptor system in the control of cortical/limbic function. The presence of Y5 immunoreactivity on cell bodies and proximal dendritic processes in specific regions of the hippocampus suggests that this receptor functions to modulate postsynaptic activity. These data also suggest that the neuropeptide Y/Y5 system may play a role in the modulation of a specific population of GABAergic neurons in the cortex, namely those that contain corticotropin-releasing hormone. The location of the Y5 receptor immunoreactivity fits with the known physiological actions of neuropeptide Y and this receptor.

The distribution of FMRFamide-like immunoreactive (ir) neurons and fibers was investigated in the central nervous system of developing zebrafish and juvenile sturgeon (sterlet). Adult zebrafish was also studied. In zebrafish embryos FMRFamide-ir elements first appeared 30 h post-fertilization (PF). Ir somata were located in the olfactory placode and in the ventral diencephalon. FMRFamide-ir fibers originating from diencephalic neurons were found in the ventral telencephalon and in ventral portions of the brainstem. At 48 h PF, the ir perikarya in the olfactory placode displayed increased immunoreactivity and stained fibers emerged from the somata. At 60 h PF, bilaterally, clusters of FMRFamide-ir neurons were found along the rostro-caudal axis of the brain, from the olfactory placode to rostral regions of the ventro-lateral telencephalon. At 60 h PF, numerous ir fibers appeared in the dorsal telencephalon, optic lobes, optic nerves, and retina. Except for ir fibers in the hypophysis at the age of 72 h PF, and a few ir cells in the nucleus olfacto-retinalis (NOR) at the age of 2 months PF, no major re-organization was noted in subsequent ontogenetic stages. The number of stained NOR neurons increased markedly in sexually mature zebrafish. In adult zebrafish, other ir neurons were located in the dorsal zones of the periventricular hypothalamus and in components of the nervus terminalis. We are inclined to believe that neurons expressing FMRFamide originate in the olfactory placode and in the ventricular ependyma in the hypothalamus. On the same grounds, a dual origin of FMRFamide-ir neurons is inferred in the sturgeon, an ancestral bony fish: prior to the observation of ir cells in the nasal area and in the telencephalon stained neurons were noted in circumventricular hypothalamic regions.

An overview of the role of ventrolateral medulla (VLM) in regulation of cardiovascular activity is presented. A summary of VLM anatomy and its functional relation to other areas in the central nervous system is described. Over the past few years, various studies have investigated the VLM and its involvement in cardiovascular regulation during static muscle contraction, a type of static exercise as seen, for example, during knee extension or hand-grip exercise. Understanding the neural mechanisms that are responsible for regulation of cardiovascular activity during static muscle contraction is of particular interest since it helps understand circulatory adjustments in response to an increase in physical activity. This review surveys the role of several receptors and neurotransmitters in the VLM that are associated with changes in mean arterial pressure and heart rate during static muscle contraction in anesthetized animals. Possible mechanisms in the VLM that modulate cardiovascular changes during static muscle contraction are summarized and discussed. Localized administration of an excitatory amino-acid antagonist into the rostral portion of the VLM (RVLM) attenuates increases in blood pressure and heart rate during static muscle contraction, whereas its administration into the caudal part of the VLM (CVLM) augments these responses. Opioid or 5-HT1A receptor stimulation in the RVLM, but not in the CVLM, attenuates cardiovascular responses to muscle contraction. Furthermore, intravenous, intracerebroventricular or intracisternal injection of an alpha 2-adrenoceptor agonist or a cholinesterase inhibitor attenuates increases in blood pressure and heart rate during static muscle contraction. Finally, the possible involvement of endogenous neurotransmitters in the RVLM and the CVLM associated with cardiovascular responses during static muscle contraction is discussed. An overview of the role of the VLM in the overall cardiovascular control network in the brain is presented and critically reviewed.

Neuropeptide Y (NPY) modulates cardiovascular, feeding and reproductive functions. Peripheral neurohumoral inputs from these systems are integrated and transformed into efferent signals in the brainstem. Detailed mapping of NPY-expressing cells in the brainstem has not been established in primates. In this report we utilized the in situ hybridization (ISH) method to identify brainstem areas that contain NPY mRNA in four ovariectomized rhesus macaques treated with estradiol-17beta. A 35S-labeled human NPY cRNA probe was used for ISH in paraformaldehyde-fixed brainstem blocks that were sectioned at 20 microm thickness. In the upper cervical spinal cord, NPY mRNA signals were confined to the substantia gelatinosa along the spinal tract of the trigeminal nerve. In the medulla, NPY images were found in the nucleus of solitary tract, dorsal motor nucleus of vagus nerve, nucleus of the spinal tract of trigeminal nerve, lateral reticular nucleus and the reticular formation. In the pons, NPY mRNA was confined to cells in the locus coeruleus and the nucleus of raphe. NPY signals were observed in the ventral portion of the periaqueductal grey, the dorsal nucleus of raphe and the reticular formation of mesencephalon in the midbrain. Whereas the brainstem distribution of NPY-containing cells in the rhesus macaque overlap those regions that are rich in catecholamines, NPY perikarya were also present in 'noncatecholaminergic' areas. For example, the reticular formation of both the medulla and mesencephalon abundantly expressed NPY mRNA. The functional significance of, and the effects of estrogen on, these patterns in NPY expression is unknown.

Neuropeptide Y (NPY) is found in cell bodies of neurons in the brain and co-localized with noradrenaline (NA) in sympathetic nerves as well as with NA and adrenaline (A) in the adrenal chromaffin cells. The purpose of the present work is to determine whether NPY and catecholamines found in the plasma of the rat under resting and stress conditions (ether inhalation, restraint) arise from the adrenals or from extra-adrenal sites. We used adrenalectomized (adx) rats and sham-adx ones. Adrenalectomy increased plasma adrenocorticotrophic hormone (ACTH) levels but decreased drastically circulating corticosterone (B) and A (-97%). However, resting NA was slightly but not significantly decreased and NPY not affected. Ether inhalation (3 min) increased plasma levels of ACTH, B, NA and A in sham-adx rats, ACTH, NA and, weakly, A in adx ones. Restraint (30 min) increased B, NA and A in sham-adx rats, NA and, poorly, A, in adx ones. In contrast, plasma levels of NPY were not significantly affected by these stress conditions. The present data suggest that NA found in rat plasma at rest and during ether or restraint stress could arise from both adrenal medulla and noradrenergic nerve endings while A arises mainly from the adrenergic chromaffin cells of the adrenals. In contrast, NPY found in the circulation, at rest and under stress conditions, is not derived from the adrenals but emanates mainly from an extra-adrenal source.

The distribution of nitric oxide producing neurones in the medulla oblongata of the cat was investigated using nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase histochemistry, and nitric oxide synthase (NOS) immunohistochemistry. The pattern of staining obtained with both methods was found to be similar. Strongly diaphorase and NOS reactive neurones were present in the paramedian and lateral tegmental fields, including the regions occupied by the A1/C1 catecholamine cell groups, the nucleus ambiguus and lateral reticular nucleus, and in a number of sensory nuclei including the nucleus of the tractus solitarius and the dorsal column nuclei. The extent of co-localization of NADPH-diaphorase with a number of neuropeptides and neurotransmitters was investigated by combining NADPH-diaphorase histochemistry with immunocytochemistry for neuropeptide Y, somatostatin, glutamate, cholecystokinin and tyrosine hydroxylase. NADPH-diaphorase reaction product was observed in neurones immunoreactive for glutamate and somatostatin. These double-labelled cells were found in the paramedian region, lateral reticular field, the nucleus prepositus hypoglossi and in the rostral nucleus of the tractus solitarius. In the rostral ventrolateral medulla NADPH-diaphorase/somatostatin immunoreactive cells were found in the paragigantocellular nucleus. NADPH-diaphorase/glutamate immunoreactive cells overlapped the nucleus ambiguus, the lateral reticular nucleus and the A1/C1 catecholaminergic cell groups. In addition, a few NADPH-diaphorase/glutamate immunoreactive cells were found in the paraolivary area and gigantocellular tegmental field, in the external cuneate and infratrigeminal nuclei. The functional implications of the co-localization of nitric oxide with these neurotransmitters in areas of the medulla concerned with cardiovascular regulation is discussed.

Neuropeptide Y (NPY) acts in the central nervous system to regulate gastrointestinal functions in rats and dogs. The effects of intracisternal injection of NPY on bile secretion and biliary components were investigated in urethane-anesthetized rats with bile duct cannula. Intracisternal NPY (0.02-0.12 nmol) dose-dependently increased bile secretion by 9.2-19.5%. The secretory response occurred within the first 20-40 min and lasted for the 120-min observation period. Intravenous injection of NPY (0.12 nmol) did not modify bile secretion under identical conditions. Biliary bile acid, phospholipid, and cholesterol secretion were not modified by intracisternal injection of NPY (0.12 nmol), whereas bicarbonate was increased by 19.0 +/- 1.7% from 40 to 120 min after NPY injection. Cervical cord transection at the C6 level, acute bilateral adrenalectomy (-120 min), or injection of NG-nitro-L-arginine methyl ester (10 mg/kg, IV, -15 min), an inhibitor of nitric oxide biosynthesis, did not alter intracisternal NPY (0.12 nmol)-induced stimulation of bile secretion. Atropine (2.0 mg/kg, IP, -30 min) and bilateral cervical vagotomy (-120 min) completely abolished the stimulatory effect of intracisternal NPY (0.12 nmol) on bile secretion. These findings indicate that NPY acts in the brain to stimulate bicarbonate-dependent bile secretion through vagal and muscarinic pathways and suggest that peptides in the central nervous system may be involved in the vagal regulation of bile secretion.

The distribution of FMRFamide-like immunoreactive peptides was studied in the brain of the African lungfish, Protopterus annectens, using the indirect immunofluorescence technique. The main populations of FMRFamide-positive cell bodies were detected in the forebrain and in the mesencephalic tegmentum. In the telencephalon, only a small number of FMRFamide-immunoreactive neurons was localized at the level of the subpallium, in the nucleus septi medialis. The diencephalon contained two prominent groups of FMRFamide-positive cell bodies located in the preoptic and periventricular preoptic nuclei. The thalamus exhibited only scattered FMRFamide-immunoreactive perikarya in its ventral part. In the mesencephalon, a group of positive cell bodies was identified in the caudal region of the tegmentum. A strong immunoreaction was also detected in the nervus terminalis. In the pituitary, most of the cells of the intermediate lobe were brightly stained. FMRFamide-like immunoreactive fibers and nerve terminals were widely distributed in the brain. In the telecephalon, numerous fibers were observed in several regions of the pallium and subpallium. A dense plexus of fibers was found in the hypothalamus and the thalamus. Immunoreactive fibers were seen coursing along the ventral wall of the infundibular cavity and terminating in the pars nervosa of the pituitary. The tectum and the ventral mesencephalon were also densely innervated. In contrast, the caudal brainstem only showed scarce immunoreactive processes. Coexistence of FMRFamide- and neuropeptide Y-like immunoreactivity was observed in the preoptic nucleus and in the nervus terminalis. The widespread distribution of FMRFamide-immunoreactive neurons in the brain and pituitary of P. annectens suggests that the peptide may exert both neuromodulator and neuroendocrine functions. The similarity between the distribution patterns of FMRFamide and neuropeptide Y in the brain of lungfish and amphibians supports the concept of a close phylogenetic link between these two groups.

The distribution and origin of neuropeptide Y in the major salivary glands of the rat was studied by indirect immunofluorescence technique. Numerous nerve fibres immunoreactive for the peptide were seen in the parotid and sublingual glands. Most of the fibres were located around blood vessels and salivary acini. In the submandibular gland the number of immunoreactive nerve fibres around the acini was lower in comparison with that in the parotid and sublingual glands. Some immunoreactive nerve fibres were also found around or along intra- and interlobular ducts in all major salivary glands. A large number of the neuropeptide-containing neuronal cell bodies and nerve fibres were detected in the sympathetic superior cervical ganglion. Sympathetic postganglionic nerve trunks of this ganglion contained numerous immunoreactive nerve fibres as well. A subpopulation of the neuronal cell bodies in the submandibular ganglion were immunoreactive to neuropeptide Y. Both uni- and bilateral superior cervical ganglionectomies caused a significant decrease in the number of immunoreactive nerve fibres around the blood vessels in all the major salivary glands. However, these denervations did not affect the density of nerve fibres around the acini and ducts. On the contrary, unilateral parasympathetic denervation by sectioning the auriculotemporal nerve reduced the fibres around the secretory acini in the parotid gland remarkably, while only a minor reduction in the density of immunoreactive fibres associated with the blood vessels of the gland was detected. Unilateral electrocoagulation of the trigeminal nerve branches caused no detectable change in the density of immunoreactive nerve fibres in any of the major salivary glands.(ABSTRACT TRUNCATED AT 250 WORDS)

The organization of neuropeptide Y-containing profiles in the dorsal horn of cat lumbosacral spinal cord was examined in an immunocytochemical study employing a specific antiserum against neuropeptide Y. Light-microscopic inspection revealed heavy concentrations of immunoreactive axons and varicosities within the superficial layers of the dorsal horn (laminae I and II) and only low to moderate numbers of positive terminals in the deeper layers (laminae III-VI). Neuropeptide-Y immunoreactivity in the superficial laminae occurred primarily as single punctate terminals, although in sagittal sections long rostrocaudally orientated fibres were also found. Immunoreactive fibres in the deeper layers were usually long and beaded. Two-hundred and eight neuropeptide Y-immunoreactive profiles throughout laminae I-VI were examined through serial sections with the electron microscope, and the overwhelming majority (n = 194) was confirmed to be axon terminals, most of which (95%) formed synaptic junctions. These terminals were packed with small irregularly shaped agranular vesicles, together with a number of large dense-core vesicles. Immunoreactivity was homogeneously scattered throughout the cytoplasm, and was also associated with the dense-core vesicles. A few neuropeptide Y-containing profiles (n = 14) were difficult to classify but they could have been vesicle-containing dendrites. The postsynaptic targets of neuropeptide Y-positive terminals were similar throughout each dorsal horn lamina. Most frequently, neuropeptide Y-positive boutons formed axodendritic and axosomatic synaptic junctions (range = 64% of synapses in laminae V/VI to 83% in lamina III). A smaller proportion of synapses were found upon other axon terminals and in laminae I-III the postsynaptic axon terminals were sometimes the central boutons of glomeruli. A number of terminals, especially those in lamina II, formed multiple synapses which often comprised a triadic arrangement. These findings suggest that neuropeptide Y regulates spinal sensory transmission through both a postsynaptic action upon dorsal horn neurons and a presynaptic action upon primary afferent terminals.

Immunohistochemistry and retrograde tracing using cholera toxin B subunit colloidal gold (CTB-gold) has been used to identify neurons in the medulla that contain neuropeptide Y and project to the area of the intermediolateral cell column in either the upper (T2-T4) or the lower (T8-T9) thoracic spinal cord. The rostrocaudal distributions of neuropeptide Y neurons and neuropeptide Y/CTB-gold neurons have been compared with the distributions of adrenaline-synthesising, phenylethanolamine N-methyltransferase-containing neurons and phenylethanolamine N-methyltransferase/CTB-gold neurons visualised in adjacent sections. In particular areas of the rostral medulla similarities in the numbers and distributions of neuropeptide Y neurons and phenylethanolamine N-methyltransferase neurons suggested a coexistence of the peptide within the catecholamine neurons. However, at the most rostral levels of the rostral ventral medulla, the large numbers of phenylethanolamine N-methyltransferase neurons were not matched by similar numbers of neuropeptide Y neurons, so that the phenylethanolamine N-methyltransferase neurons in this area could not all contain neuropeptide Y. In the rostral ventral medulla fewer neuropeptide Y/CTB-gold neurons than phenylethanolamine N-methyltransferase/CTB-gold neurons were observed, so that these bulbospinal peptide neurons might define a subset of the phenylethanolamine N-methyltransferase/CTB-gold neurons, accounting for 25% of the total phenylethanolamine N-methyltransferase bulbospinal projection from the rostral ventral medulla. Other neuropeptide Y/CTB-gold neurons in the dorsal medulla are also likely to contain phenylethanolamine N-methyltransferase. Finally, a population of neuropeptide Y/CTB-gold neurons was identified in the caudal ventral medulla, these neurons appear not to contain catecholamine synthesising enzymes.

The effects of two Neuropeptide Y (NPY) analogs (Y1- and Y2-type) and vasoactive intestinal peptide (VIP) on both catecholamine (adrenaline and noradrenaline) release and aldosterone production by rat adrenal capsule/glomerular zone, have been investigated in vitro. The adrenal capsule/glomerular zones, collected from adult male rats, were incubated in a medium (Krebs-Ringer bicarbonate buffer supplemented with glucose and bovine serum albumin) containing or not one of the following synthetic peptides: human Leu31,Pro34-NPY (an agonist of the Y1-type receptors), human/porcine NPY18-36 (an agonist of the Y2-type receptors) and VIP at the concentration of 10(-7) M, associated or not with 10(-7) M atenolol (a beta 1 adrenergic antagonist) or ICI-118,551 hydrochloride (a beta 2 adrenergic antagonist). The two NPY analogs as well as the VIP stimulated the release of catecholamines and of aldosterone. The beta 1 adrenergic antagonist, but not the beta 2 one, which failed to affect basal aldosterone production when given alone, prevented NPY18-36-, Leu31,Pro34-NPY- or VlP-induced aldosterone secretion. Present data support the hypothesis that adrenaline and/or noradrenaline could mediate the effects of both NPY and VIP on aldosterone secretion via beta 1 adrenergic receptors; alternatively, the steroidogenic effect of NPY or VIP could be related to direct interaction between NPY- or VIP-specific binding sites, present on the capsule/glomerular zone of the rat adrenal cortex, and beta 1 adrenergic receptors. Then the NPYergic, VIPergic and catecholaminergic innervation of the adrenal cortex, previously characterized by immunohistochemistry, may be a potent stimulatory element in the nervous control of the aldosterone secretion.

The distribution of FMRFamide-like immunoreactive peptides was investigated in the brain of the lizard, Podarcis sicula, using the indirect immunofluorescence technique. The main populations of FMRFamide-immunoreactive cell bodies were located in the forebrain. In the telencephalon, FMRFamide-containing neurons were found both in the pallium and subpallium, namely in the medial cortex, the anterior olfactory nucleus, the nucleus accumbens, the septal nuclei, the nucleus of the medial forebrain bundle, and the nucleus of the diagonal band of Broca. In the diencephalon, a dense accumulation of FMRFamide-immunoreactive neurons was observed in the area preoptica lateralis, the nucleus suprachiasmaticus, the nucleus periventricularis hypothalami, the area lateralis hypothalami, and the dorsal region of the nucleus geniculatus lateralis. In the midbrain, sparse immunoreactive perikarya were found in the tegmentum of the mesencephalon. FMRFamide-immunoreactive fibers were visualized in all regions containing positive cell bodies. In particular, dense bundles of immunoreactive processes were seen in the area preoptica lateralis, in the hypothalamus, and in the median eminence. The tectum and the basal mesencephalon were also densely innervated. Conversely, the caudal brain stem only exhibited scarce immunoreactive processes. The distribution pattern of FMRFamide-immunoreactive neurons in the brain of Podarcis sicula exhibits a number of similarities with that reported in mammals, but significantly differs from that reported in amphibians and fish, suggesting that the neuromodulatory functions of FMRFamide may have diverged during the emergence of terrestrial life.

The efficacy of NPY to elicit feeding in TB rats was reduced prior to the onset of overt anorexia, with the feeding response decreasing further as anorexia developed. Hypothalamic concentration of NPY was reduced in TB rats, with the magnitude of the decrease paralleling the degree of anorexia. Binding affinity of NPY to hypothalamic membranes taken from TB rats suggested decreased binding affinity with no change in receptor number. Infusing ammonium salts at a concentration and rate necessary to increase blood ammonia levels to the degree observed in TB rats, produced anorexia and decreased NPY feeding. These results suggest that NPY feeding systems are abnormal in TB rats and that hyperammonemia may be of primary importance in this dysfunction.

Immunocytochemical localization of the protein product of the proto-oncogene c-fos allows anatomical identification of physiologically activated neurons. The present study examined the subnuclear distribution of cFos protein in the rat caudal medulla following peripheral administration of cholecystokinin octapeptide, which reduces feeding and gastric motility by a vagally mediated mechanism. To begin phenotypic characterization of neurons activated to express cFos following cholecystokinin treatment, double-labeling techniques were used to identify vagal motor neurons and neurons immunoreactive for tyrosine hydroxylase, neuropeptide Y, and neurotensin. Activated cells were most prevalent in the subnucleus medialis of the nucleus of the solitary tract, less prevalent in the subnucleus commissuralis, and virtually absent in the subnuclei centralis and gelatinosus. Many activated cells occupied the caudal area postrema; some of these were catecholaminergic. In contrast, activated cells were sparse within the medial rostral area postrema. Other activated cells occupied the dorso- and ventrolateral medulla and the midline raphe nuclei. Retrograde labeling of vagal motor neurons confirmed that very few were activated. Those that were activated occupied the caudal dorsal motor nucleus. In the dorsomedial medulla, 51% of catecholaminergic neurons and 39% of neurons positive for neuropeptide Y were activated, but no neurotensin-positive neurons were activated. In the ventrolateral medulla, 25% of catecholaminergic neurons and 27% of neuropeptide Y-positive neurons were activated. By characterizing the subnuclear distribution and chemical phenotypes of neurons activated by exogenous cholecystokinin, these data contribute to elucidation of the neural circuits mediating the behavioral, physiological, and neuroendocrine effects produced by this peptide.

The effects of NPY(13-36) on cardiorespiratory responses elicited by microinjections of L-glutamate into the nucleus tractus solitarius (NTS) have been studied in anaesthetized (alpha-chloralose + urethane) Sprague-Dawley rats. NPY(13-36) in doses ranging from 50 to 500 fmol produces a significant increase in mean arterial pressure (MAP) without significant effects on heart rate (HR) and respiratory rate (RR). The ED50 dose (100 fmol) of NPY(13-36) counteracts significantly the decrease in MAP and HR elicited by L-glutamate (1500 pmol) microinjected into NTS. Similar results are obtained using a threshold dose of the peptide (50 fmol) and an ED50 dose of L-glutamate (300 pmol). These results indicate that the Y2 receptors in NTS can mediate vasopressor responses to femtomolar amounts of NPY(13-36) and counteract cardiovascular responses to L-glutamate.

The parvicellular compartments of the paraventricular nucleus of the hypothalamus (pPVN) contains particularly high concentrations of neuropeptide (NPY)-containing fibres of two main cellular origins including (i) neurons of the medulla oblongata, most of which co-store phenylethanolamine-N-methyltransferase (PNMT), the enzyme characterizing adrenergic neurons, and (ii) non-catecholaminergic neurons of the mediobasal hypothalamus. The aim of the present study is to compare the fine organization of the two types of axons terminating in the pPVN. Immunocytochemistry at light and electron microscope levels was used to study both the density and the ultrastructural organization of NPY- and PNMT-immunoreactive fibres in the pPVN of animals bearing surgical lesions disrupting axonal pathways from the hindbrain or from the sublying mediobasal hypothalamus. The brainstem knife-cut induced a strong decrease (65%) in the numerical density of PNMT fibres innervating the pPVN, but was without significant effects on the density of NPY fibres. On the other hand, the hypothalamic knife-cut induced an 80% decrease in the density of NPY fibres within the PVN without affecting the number of PNMT fibres. The electron microscope study showed that in the control pPVN contralateral to the lesions, the majority (64%) of PNMT synapses were asymmetric axo-dendritic synapses, whereas the majority (67%) of NPY synapses form symmetric contacts with both dendrites and perikarya of the hypothalamic nucleus. By contrast, after a hypothalamic knife-cut, the majority (66%) of NPY synapses identified in the pPVN exhibited features of asymmetric synapses. These data indicate that the large majority of NPY-immunoreactive fibres detected within the pPVN arise from non-catecholaminergic neurons located in the mediobasal hypothalamus and mainly form symmetric synapses on neurons of the pPVN, whereas only a minority of them arise from hindbrain regions, and like PNMT fibres innervating this nucleus preferentially form asymmetric axo-dendritic synapses.

This study investigated the effect of paraventricular nucleus (PVN) injection of neuropeptide Y (NPY) on milk and water intake of 2- and 15-day-old sated rats. On the day prior to testing, rat pups were removed from their mothers and implanted with a cannula directed unilaterally at the PVN. On the following day, each pup was implanted with an intra-oral cannula for oral infusion of milk or water that could be swallowed or rejected. Following a 1-hour period fo satiation, each pup received a PVN injection of saline or a single dose of NPY (23.5-235.0 pmol). Milk or water intake was then assessed in a 1-hour test period. Injection of NPY into the PVN enhanced milk and water intake equally at 2 days of age. At 15 days, NPY produced a significantly greater enhancement of milk than water intake. These findings, which are similar to those observed previously with PVN injections of norepinephrine (NE), suggest that: (1) NPY receptors in the PVN, like alpha 2-noradrenergic receptors, are functional very early in the postnatal development of the rat; (2) NPY, in addition to its orexigenic effect, produces a small but significant dipsogenic effect; and (3) NPY may function cooperatively with NE in the PVN to stimulate feeding and drinking beginning at a very early age.

Peptide YY (PYY) was demonstrated by immunochemical and/or immunocytochemical methods in endocrine cells in the pancreas of adult mice, rats, guinea-pigs, cats, dogs, pigs and cows. In the pancreas of mouse and rat, immunoreactive PYY was observed in a major subpopulation of the glucagon cells (splenic lobe of the pancreas); immunoreactive PYY also occurred in a subpopulation of the pancreatic polypeptide (PP) cells (duodenal lobe), and in a few extra-insular endocrine cells dispersed throughout the pancreatic parenchyma. In the pancreas of cat, dog and pig immunoreactive PYY was found to coexist with PP, but not with glucagon. Radioimmunoassay (RIA) revealed PYY-like material in extracts of pancreas (and colon) of all the species examined. The highest concentrations were found in the pancreas of cat and mouse; moderate amounts were found in the rat and only small amounts were detected in guinea-pig and pig. The concentrations in the pancreas were uniformly much lower than those in the colon. Analysis by high performance liquid chromatography (HPLC) showed that the PYY-immunoreactive material from pancreas (and rat colon) had an elution profile very similar to that of synthetic PYY, and distinct from that of PP and neuropeptide Y.

Immunocytochemical methods were used to identify cells and processes containing two major catecholamine (CA)-biosynthetic enzymes in areas of the canine medulla implicated in autonomic control. Antisera were employed against tyrosine hydroxylase (TH) and phenylethanolamine N-methyltransferase (PNMT). These enzymes respectively catalyze the conversions of tyrosine to L-DOPA and noradrenaline to adrenaline. Immunocytochemical studies laid the groundwork for subsequent investigations in conscious dog in which we characterized an area of cardiovascular control in the rostral ventrolateral medulla (RVLM). In the anatomical studies, previously unidentified neuronal somata and processes were demonstrated in the canine medulla. Presumptive adrenergic (CI) neurons in the canine RVLM were subjacent to the nucleus ambiguous (NA) and most numerous at a level where the compact and semicompact divisions of NA merged. In contrast to their distribution in rodents, C1 neurons were skewed caudally and did not extend rostrally to the caudal pole of the facial nucleus. C1 neurons were also relatively less concentrated in the RVLM. A large number of C1 neurons extended dorsally into the lateral tegmental field (LTF). Most C1 neurons in the LTF (like those in the A1 area) were aligned with catecholaminergic (TH- and PNMT-ir) processes traversing the intermediate reticular zone. Since the numbers and locations of TH- and PNMT-ir neurons in the C1 area of the RVLM and rostral LTF were virtually identical on adjacent sections, it can be implicitly inferred that the enzymes are co-localized to the same somata and that these neurons are capable of biosynthesizing adrenaline. The C1 and A5 areas were clearly separated by a transitional zone, sparsely populated by TH-ir somata (1-2 cells per section), where the facial nucleus and rostral pole of the NA pars compacta (NAc) occupied the same level. A5 neurons were more abundant and complexly organized than suggested by previous CA-histofluorescence data. In addition, a new parvicellular subgroup was identified and composed of neurons containing TH but not PNMT. In contrast to other species, the A1 cell group was not confined to the VLM. A large number of A1 neurons extended into the caudal LTF and were situated between the nucleus tractus solitarii-motor vagal complex (NTS-X) and caudal VLM (CVLM). In contrast to previous reports, presumptive adrenergic (TH- and PNMT-ir) cell groups were more densely represented in the C2-3 areas of the canine NTS and dorsomedial reticular formation.(ABSTRACT TRUNCATED AT 400 WORDS)

The colocalization of the peptides neuropeptide Y (NPY) and Phe-Met-Arg-Phe-NH2 (FMRFamide) in the brain of the Atlantic salmon was investigated with double immunofluorescence labeling and peroxidase-antiperoxidase immunocytochemical techniques. Colocalization of NPY-like and FMRF amide-like immunoreactivities was observed in neuronal cell bodies and fibers in four brain regions: in the lateral and commissural nuclei of the area ventralis telencephali, in the nucleus ventromedialis thalami, in the laminar nucleus of the mesencephalic tegmentum, and in a group of small neurons situated among the large catecholaminergic neurons in the isthmal region of the brainstem. All cell bodies in these nuclei were immunoreactive to both NPY and FMRF. We consistently observed larger numbers of FMRF-immunoreactive than NPY-immunoreactive fibers. In the nucleus ventromedialis thalami NPY- and FMRFamide-like immunoreactivities were colocalized in cerebrospinal fluid (CSF)-contacting neurons. NPY-immunoreactive, but not FMRF-immunoreactive, neurons were found in the stratum periventriculare of the optic tectum, and at the ventral border of the nucleus habenularis (adjacent to the nucleus dorsolateralis thalami). Neurons belonging to the nucleus of the nervus terminalis were FMRF-immunoreactive but not NPY-immunoreactive. The differential labeling indicates, as do our cross-absorption experiments, that the NPY and FMRFamide antisera recognize different epitopes. Thus, it is probable that NPY-like and FMRF amide-like substances occur in the same neurons in some brain regions.

We utilized a model of fluid percussion (FP) brain injury in the rat to examine the hypothesis that alterations in brain neuropeptide Y (NPY) concentrations occur following brain injury. Male rats (n = 44) were subjected to FP traumatic brain injury. One group of animals (n = 38) was killed at 1 min, 15 min, 1 h, or 24 h after brain injury, and regional brain homogenates were analyzed for NPY concentrations using radioimmunoassay. A second group of animals (n = 6) was killed for NPY immunocytochemistry. Concentrations of NPY in the injured left parietal cortex were significantly elevated at 15 min post injury (p less than 0.05). No changes were observed in other brain regions. NPY-immunoreactive fibers were seen at 15 min post injury predominantly in the injured cortex and adjacent hippocampus. These temporal changes in NPY immunoreactivity, together with previous observations concerning posttraumatic changes in regional CBF in these same areas, suggest that an increase in region NPY concentrations after brain injury may be involved in part in the pathogenesis of posttraumatic hypoperfusion.

Subtypes of the neuropeptide Y (NPY) receptor in the rat brain were identified by the use of the selective Y-1 analog, [Leu34-Pro34] NPY. In rat brain homogenate binding studies, [Leu31-Pro34] NPY was found to produce a partial inhibition of 100 pM 125I-labeled peptide YY (PYY) binding with a plateau at 50-1000 nM [Leu31-Pro34] NPY resulting in a 70% inhibition of binding. The C-terminal fragment NPY 13-36, a putative Y-2 agonist, exhibited very little selectivity in rat brain homogenates. Scatchard analysis of 125I-labeled PYY binding to rat brain homogenate yielded biphasic plots with Kd values of 40 and 610 pM. Inclusion of 100 nM [Leu31-Pro34] NPY was found to eliminate the low affinity component of 125I-labeled PYY binding leaving a single, high affinity binding site with a Kd of 68 pM. In autoradiographic studies, displacement curves indicated that [Leu31-Pro34] NPY completely inhibited binding in the cerebral cortex with little effect on the binding in the hypothalamus. On the other hand NPY 13-36 inhibited binding in the hypothalamus at low concentrations but required higher concentrations to inhibit binding in the cerebral cortex. Other brain regions such as the hippocampus, appeared to contain both subtypes. Subsequent to these studies, a quantitative autoradiographic map was conducted using 50-100 pM 125I-labeled PYY in the presence and absence of [Leu31-Pro34] NPY which produced a selective displacement of binding in certain distinct brain regions. These areas included the cerebral cortex, certain thalamic nuclei and brainstem while ligand binding was retained in other brain regions including the zona lateralis of the substantia nigra, lateral septum, nucleus of the solitary tract and the hippocampus. Numerous brain regions appeared to contain both receptor subtypes. Therefore, the Y-1 and Y-2 receptor subtypes exhibited a somewhat distinct distribution in the brain. In addition, 125I-labeled PYY appears to label the Y-2 receptor with relatively higher affinity when compared to the Y-1 receptor.

The 36 amino acid neuropeptide Y (NPY) has been examined in mammals and is mainly located in the nerves. Its distribution in nonmammalian vertebrate and in some invertebrate nervous systems has been confirmed. Using antisera raised to porcine NPY, NPY immunoreactivity has been localized in endocrine cells of the pancreas and gastrointestinal tract of two dogfish, Scyliorhinus stellaris and Scyliorhinus canicula. Immunostained serial sections and cross-absorption experiments with related peptides, including avian and bovine pancreatic polypeptide and peptide tyrosine tyrosine, excluded any cross-reactivity. The fine structure of the cells containing NPY-like substance is described.

Neuropeptide Y (NPY), first isolated in 1982, is widely distributed among the neurons of the central and peripheral nervous systems, often in close association with catecholamines. Because of its wide distribution and concentrations in selected areas of the brain, NPY is considered a putative neurotransmitter with several possible physiological effects including modulation of blood pressure, food intake and pituitary hormone release at a central level. Peripherally, the peptide seems to be involved, via direct and indirect mechanisms, in noradrenaline (NA)-mediated vasoconstriction. The ability of NPY to interact with the catecholamine transmission line may underly a possible modulatory influence of NPY on catecholamine receptor characteristics. We recently observed interaction between alpha-2 adrenergic receptors and those for NPY at the presynaptic level. Additional data from our studies in spontaneously hypertensive rats suggest that impairment of these interactions may contribute to the hypertension in this strain.

1. Monoamine turnover and neuropeptide Y (NPY) levels were investigated in the central and peripheral nervous systems in adult male rats chronically treated with codeine. 2. An increase in the dopaminergic turnover was observed in the striatum and cortex. The norepinephrine levels and the serotoninergic turnover were unchanged in all the brain areas. 3. Epinephrine levels were decreased in the adrenal glands. 4. In addition, we observed a significant decrease of NPY levels in the hypothalamus, the striatum and the adrenal glands. These observed changes were not found when assessing NPY level in plasma fluid. 5. The implication of these modifications in the induction of codeine dependence are discussed in view of previous results obtained with morphine.

The anatomical distribution of FMRFamide-like immunoreactivity in the forebrain and pituitary of the catfish, Clarias batrachus, was investigated. Immunoreactive cells were observed in the ganglion cells of the nervus terminalis (NT) and in the medial olfactory tracts. In the preoptic area, FMRFamide-containing perikarya were restricted to the lateral preoptic area, paraventricular subdivision of the nucleus preopticus, nucleus suprachiasmaticus and nucleus preopticus periventricularis posterior. In the postoptic area, some cells of the nucleus postopticus lateralis and nucleus of the horizontal commissure showed moderate immunoreactivity. In the tuberal area, immunoreactivity was observed in few cells of the nucleus hypothalamicus ventralis and nucleus arcuatus hypothalamicus (NAH). Nucleus ventromedialis thalami was the only thalamic nucleus with FMRFamide immunoreactivity. Immunoreactive processes were traceable from the NT through the medial as well as lateral olfactory tracts into the telencephalon and the area ventralis telencephali pars supracommissuralis (Vs). Further caudally, the immunoreactive fibers could be traced into discrete areas, including habenular and posterior commissures, neurohypophysis and pituitary; isolated fibers were also observed in the pineal stalk. A loose network of immunoreactive processes was observed in the olfactory bulbs and the entire telencephalon, with higher densities in some areas, including Vs. A dense plexus of immunoreactive fibers was seen in the pre- and postoptic areas and around the paraventricular organ, while relatively few were observed in the thalamus. A high concentration of fiber terminals was found in the caudal tuberal area.

Adult male Sprague-Dawley rats were injected with either 6-hydroxydopamine (6-OHDA) or vehicle in the median preoptic nucleus and the organum vasculosum of the lamina terminalis. The subjects were tested for drinking responses to intraventricular angiotensin II (ANG II) or saline during either saline or norepinephrine intraventricular infusions. Rats injected with 6-OHDA into the ventral lamina terminalis initially failed to show drinking responses to ANG II injections. However, norepinephrine infusion in combination with ANG II injection restored the drinking response to ANG II in rats with catecholamine depletions of the lamina terminalis region.

Immunocytochemistry was used to compare the immunoreactivity of adrenergic neurons to a well characterized specific immunoserum to phenylethanolamine-N-methyltransferase (PNMT) in different strains of rats commonly used in research studies. In adult animals, marked differences were found in the PNMT-immunoreactivity of neurons between Wistar rats and other strains, resulting in a lower PNMT-immunostaining intensity (i) within neuronal perikarya of the medulla oblongata, and (ii) more strikingly, within nerve fibers and terminals located in various brain regions. This low PNMT-immunoreactivity of nerve fibers was detected both in 14- and 35-day-old Wistar rats. On the other hand, the HPLC measurement of catecholamines, in particular of adrenaline in the hypothalamus and the medulla oblongata, did not show any difference between adult Wistar and Sprague-Dawley rats. These data suggest that the low PNMT-immunoreactivity observed in central adrenergic neurons of the Wistar rats is related to the poor recognition of the antigen by the PNMT-antibody used. Possibly, these nerve cells mainly display an isoform of the enzyme that is immunologically different from the PNMT contained within the adrenergic neurons of other rat strains.

Central administration of neuropeptide Y (NPY) induces food intake in freely feeding animals and this effect is mediated by hypothalamic sites. Little is known, however, about the effect of NPY on food intake and site of action in food-deprived animals. To examine this further, 24-h fasted rats received injections of saline or NPY into the lateral cerebral ventricle (10 micrograms/10 microliters; n = 8) or into the lateral (LH) or ventromedial hypothalamus (VMH) (1 microgram/0.5 microliters; n = 44). In addition, intracerebroventricular (i.c.v.) injections of NPY were carried out with or without i.c.v. naloxone (25 micrograms), a specific opioid receptor antagonist. During the first 40 min food intake was not different with or without NPY. After 60 and 120 min, food intake was 5.9 +/- 0.4 g and 8.3 +/- 0.6 g with i.c.v. saline which was significantly augmented by i.c.v. NPY to 8.7 +/- 0.9 g and 14.4 +/- 1.5 g, respectively (P less than 0.05). This increase in food consumption was due to a prolongation of feeding time. The opioid receptor antagonist naloxone significantly augmented latency to feed, both in the absence and presence of NPY (8.0 vs 1.7 min or 14.7 vs 2.8 min, respectively) and abolished the NPY-induced increase in food intake. Following intrahypothalamic injection of NPY, an increase in food intake (greater than 20%) was observed in 50% of the histologically identified LH and VMH sites, but only in 15% of the injection sites outside the LH/VMH.(ABSTRACT TRUNCATED AT 250 WORDS)

The effects of peripheral axotomy (sciatic nerve transection) on the presence and distribution of neuropeptide Y (NPY) in rat dorsal root ganglion (DRG) and spinal grey matter were examined using immunocytochemistry. In normal rats and on the sham-operated side of experimental rats, NPY-like immunoreactivity (NPYir) was observed in all laminae of the lumbar spinal cord, with an especially dense concentration of immunostained axons and axonal varicosities in laminae I-II of the dorsal horn. There was no detectable NPYir in L4-L5 DRG cells from normal rats or from the sham-operated side of experimental rats. At 14 days after axotomy, there was a large ipsilateral increase in the density of NPYir axons and varicosities in the lumbar spinal cord on the side of the nerve injury; this was especially apparent in laminae III-V. In the same rats, NPYir was observed in many small, medium, and large neurons in the L4-L5 DRGs on the side of the severed nerve.

The central cardiovascular responses induced by neuropeptide Y (0.25 nmol) and adrenaline (2.00 nmol) given i.c.v. in close to maximal doses in the awake, unrestrained male rat were studied following changes in the pituitary-adrenal activity. Adrenalectomy (1 week) alone significantly reduced the vasodepressor response to i.c.v. adrenaline but not to i.c.v. neuropeptide Y. Corticosterone replacement treatment (5 mg kg-1 x 2, i.p., 1 week) significantly reduced both the maximal (peak) and overall (area) vasodepressor responses to i.c.v. adrenaline and neuropeptide Y (only overall responses) in the adrenalectomized rat. Corticosterone treatment alone in the sham-operated rat highly significantly reduced the vasodepressor responses to both i.c.v. adrenaline and neuropeptide Y. The bradycardic action of centrally administered neuropeptide Y was no longer significant after alterations in pituitary-adrenal activity. The present results suggest that corticosterone treatment can abolish the centrally evoked vasodepressor responses to close to maximal doses of adrenaline and neuropeptide Y, which may contribute to their hypertensive properties in man. Finally, after adrenalectomy the central vasodepressor responses to neuropeptide Y dominate, since the adrenergic vasodepressor responses are selectively reduced. This dominance is reduced by corticosterone replacement treatment. The results indicate an antagonistic role of adrenocortical steroids in control of centrally induced acute vasodepressor responses to neuropeptide Y and adrenaline.

Neurons in the ventrolateral medulla oblongata of rats, guinea-pigs and cats that contain tyrosine hydroxylase, dopamine-beta-hydroxylase, phenylethanolamine-N-methyltransferase and neuropeptide Y have been demonstrated immunohistochemically in serial coronal sections of tissue taken from the level of the cervical spinal cord to the level of the facial nucleus. The anatomical distribution of these neurons has been described, quantified and reconstructed in three dimensions to compare the neuron populations between species. In all species, between 50 and 90% of immunoreactive neurons lay rostral to the level of the obex. There were no significant differences in the number and distribution of neurons containing catecholamine-synthesizing enzymes between control animals and those pretreated with colchicine, with two exceptions: all dopamine-beta-hydroxylase neurons were weakly immunoreactive without colchicine pretreatment in cats, and pretreatment with colchicine revealed a small rostral group of tyrosine hydroxylase-positive neurons in guinea-pigs. There were remarkable similarities in the rostrocaudal distributions of neurons containing tyrosine hydroxylase, dopamine-beta-hydroxylase and neuropeptide Y in relation to comparable anatomical landmarks across the species. However, the distributions of neurons containing tyrosine hydroxylase. Phenylethanolamine-N-methyltransferase-positive neurons, while densely stained in rats, were only faintly stained in cats and absent in guinea-pigs; the distribution of these neurons was similar to the distribution of neurons containing only tyrosine hydroxylase. The similarity of the distribution of neurons demonstrated using tyrosine hydroxylase, dopamine-beta-hydroxylase and neuropeptide Y immunohistochemistry implies that homologous catecholamine-containing neuron groups do exist in the ventrolateral medulla despite the variation in phenylethanolamine-N-methyltransferase between species. In contrast to the previous classification of neuron groups into A1 and C1 based on the presence or absence of this latter enzyme, the data suggest that a discrete group of tyrosine hydroxylase-immunoreactive neurons, which probably do not contain dopamine-beta-hydroxylase or neuropeptide Y, can be distinguished in the rostral ventrolateral medulla of all species. The absence of detectable dopamine-beta-hydroxylase in this group of neurons suggests that they may not synthesize either adrenaline or noradrenaline.